Highlights

  • Lumos Diagnostics Holdings (ASX:LDX) reported FY26 Revenue of US$13.2 million, including US$4.3 million of FebriDx product revenue.
  • FebriDx received a US FDA CLIA Waiver in March 2026, expanding the settings in which the test can be used.
  • Cash at 30 June 2026 was US$15.4 million after a A$20.3 million Capital raising during FY26.

Lumos Diagnostics Holdings Limited (ASX:LDX) enters FY27 with a clearer commercial pathway for FebriDx in the United States. A CLIA waiver granted in March 2026 broadened the settings in which the rapid respiratory test can be used, while FY26 product revenue reached US$4.3 million. The company remains loss-making, so the central issue is whether commercial adoption can scale quickly enough to improve cash generation and reduce reliance on external capital.

Company Overview

Lumos Diagnostics Holdings Limited (ASX:LDX) develops and manufactures point-of-care diagnostic tests and also provides diagnostic development services. FebriDx is its lead commercial product and is designed to help distinguish bacterial from viral acute respiratory infection at the point of care.

In March 2026, the United States Food and Drug Administration granted 510(k) clearance with CLIA waiver for FebriDx. Lumos said the decision broadened access to more than 300,000 healthcare locations and opened an estimated US market opportunity above US$1.0 billion annually.

Financial and Operational Position

FY26 group revenue was US$13.2 million. FebriDx product revenue was US$4.3 million and services revenue was US$8.9 million. Gross Profit was US$7.9 million at a Margin of 60.1%.

The adjusted EBITDA loss was US$2.8 million and the net loss after tax was US$5.0 million. Cash at 30 June 2026 stood at US$15.4 million following a A$20.3 million capital raising during the year.

By FY26 year end, Lumos reported more than 170 healthcare locations across 24 US states actively ordering FebriDx, with more than 90% of claims paid. The company is also continuing work on a paediatric CLIA waiver programme.

What Investors May Watch Next

The primary FY27 measure is the pace of FebriDx order growth now that the CLIA waiver is in place. Investors may watch ordering locations, product revenue, private-payer coverage and Manufacturing scale-up.

Cash flow remains equally important. Continued losses mean commercial traction needs to translate into improved cash conversion if Lumos is to extend its funding runway without further material capital raising.

Risks

Lumos remains loss-making and increasingly dependent on the commercial performance of FebriDx. Services revenue also contributes a substantial share of group revenue and can be uneven between periods.

Private-payer reimbursement is not guaranteed, respiratory testing is seasonal, and distribution partners influence the pace of market penetration. If the commercial ramp is slower than expected, additional funding may be required.

Key Takeaways

Lumos Diagnostics Holdings (ASX:LDX) has cleared an important regulatory barrier and entered FY27 with a larger commercial footprint and improved liquidity. The next test is whether FebriDx adoption converts into sustained product revenue and a better cash profile.